Summit Therapeutics (SMMT) Payables (2018 - 2025)
Summit Therapeutics (SMMT) has disclosed Payables for 7 consecutive years, with $22.2 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Payables fell 19.84% year-over-year to $22.2 million, compared with a TTM value of $22.2 million through Sep 2025, down 19.84%, and an annual FY2024 reading of $4.6 million, up 73.83% over the prior year.
- Payables was $22.2 million for Q3 2025 at Summit Therapeutics, down from $23.0 million in the prior quarter.
- Across five years, Payables topped out at $103.3 million in Q2 2024 and bottomed at $710000.0 in Q1 2023.
- Average Payables over 5 years is $21.5 million, with a median of $6.4 million recorded in 2024.
- The sharpest move saw Payables plummeted 89.8% in 2023, then soared 10370.11% in 2024.
- Year by year, Payables stood at $4.4 million in 2021, then surged by 360.11% to $20.1 million in 2022, then crashed by 86.75% to $2.7 million in 2023, then skyrocketed by 73.83% to $4.6 million in 2024, then surged by 379.83% to $22.2 million in 2025.
- Business Quant data shows Payables for SMMT at $22.2 million in Q3 2025, $23.0 million in Q2 2025, and $5.0 million in Q1 2025.